Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.

At Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V. in Bonn, the clinical trial portfolio is centered on nervous system diseases, with a strong focus on neurodegenerative conditions affecting memory, movement, and cognition. The studies are designed to better understand disease progression and to test whether new therapies can slow decline, improve symptoms, or support earlier diagnosis.

• Alzheimer’s disease and preclinical cognitive decline
• Huntington’s disease and related inherited movement disorders
• Parkinson’s disease, Multiple System Atrophy, and Progressive Supranuclear Palsy
• Testing therapies aimed at slowing clinical progression and preserving daily function

The research includes efforts to evaluate treatment effectiveness, monitor safety, and identify biomarkers that may help track disease changes more precisely over time.

Several trials at this site focus on Alzheimer’s disease, ranging from preclinical Alzheimer’s disease to mild dementia. These studies aim to see whether investigational therapies can slow cognitive decline, protect brain function, and influence disease-related markers linked to early-stage illness.

• Preclinical Alzheimer’s disease and early symptomatic Alzheimer’s disease
• Studying approaches to delay worsening of memory and thinking skills
• Evaluating new options for cognitive impairment and disease modification

This work reflects a broader effort to improve how early Alzheimer’s disease is treated and monitored before more advanced symptoms develop.

The site also has active research in Huntington’s disease and related inherited neurodegenerative disorders, including prodromal and early manifest Huntington’s disease and spinocerebellar ataxia. These trials are looking at whether new treatments can reduce disease activity, preserve function, and improve day-to-day movement and coordination.

• Huntington’s disease and prodromal disease stages
• Spinocerebellar ataxia types 1 and 3
• Measuring impact on motor symptoms and functional decline

Research in this area is aimed at finding therapies that may better control symptoms while also addressing the underlying biology of Huntington’s disease.

Another important theme is the study of movement disorders such as early Parkinson’s disease, Multiple System Atrophy, and Progressive Supranuclear Palsy Richardson Syndrome. These trials are designed to evaluate whether emerging therapies can slow worsening movement problems and support independence for longer.

• Early Parkinson’s disease
• Multiple System Atrophy
• Progressive Supranuclear Palsy
• Assessing treatment effects on mobility, daily function, and disease progression

The overall goal is to improve care for patients with difficult-to-treat neurodegenerative movement disorders through better therapies and more reliable measures of change.

The portfolio includes research into autoimmune dementia, highlighting the role of the immune system in cognitive problems. These studies are intended to test whether immune-targeted treatment can improve thinking abilities and reduce the burden of inflammation-related brain dysfunction.

• Autoimmune dementia
• Exploring immune-modulating therapy for cognitive symptoms
• Focusing on treatment effectiveness and symptom improvement

This area broadens the site’s work beyond classic degenerative disease by examining how immune pathways may contribute to dementia-like symptoms.